MapLight Therapeutics MPLT
NASDAQ MPLT
$9.90 +0.27 (+2.80%)
As of: Oct 2, 2026 · 3:12 PM EDT

MapLight Therapeutics (MPLT) Depreciation & Amortization (CF) (2024 - 2025)

Updated

MapLight Therapeutics (MPLT) recorded Depreciation & Amortization (CF) of $162,000 in Q4 2025, down 16.5% from $194,000 a year earlier but up 62.0% from the prior quarter.

Analysis

MapLight Therapeutics (MPLT) Depreciation & Amortization (CF) (2024 - 2025) Analysis & Trends

For FY2025, MapLight Therapeutics reported Depreciation & Amortization (CF) of $600,000, down 14.4% from FY2024.

  • Across earlier years, Depreciation & Amortization (CF) came in at $701,000 in FY2024.
  • Quarterly Depreciation & Amortization (CF) has ranged from $100,000 in Q3 2025 to $200,000 in Q3 2024 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Amort. (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 1.96 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 194.00 Mn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 599.00 Mn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 1.93 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 1.11 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 98.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 1.62 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 56.50 Mn
10 MapLight Therapeutics 463.00 Mn 463.00 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 162,000.00
Sep 30, 2025 100,000.00
Dec 31, 2024 194,000.00
Sep 30, 2024 200,000.00
API Access

MapLight Therapeutics Depreciation & Amortization (CF) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=depreciation-and-amortization-cf&ticker=MPLT&period=max&api_key=YOUR_API_KEY